BMS secures FDA Priority Review for Reblozyl to treat anaemia in adults with MDS
Bristol Myers Squibb (BMS) has received the US Food and Drug Administration (FDA) Priority Review for its anaemia drug Reblozyl (luspatercept-aamt) to expand its current indication. The expanded